Floatz logo

Fostamatinib

Ovarian Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsSmall moleculePhase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
59/ 100

Competitive context

525 Active assets in the Ovarian Cancer cohort.

Asset / SponsorPhaseRating
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
TIL
Inge Marie Svane
Phase 2BB
Olaparib
Shandong University
Phase 4BB
Carboplatin
Fudan University
Phase 4BB
Irinotecan
ARCAGY/ GINECO GROUP
Phase 4BB

View all 50 →

Same molecule, other indications

Fostamatinib is also rated in:

diffuse large B-cell lymphomaDormant
CCC
Indicative ·
54 / 100
View asset →
lymphomaDormant
CC
Indicative ·
44 / 100
View asset →
Disease Sickle Cell AnemiaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →